Hot Natural Products & Bioactive Compounds
BioCrick offers high-purity natural products and bioactive compounds for scientific research. Our natural product collection includes compounds derived from plants, microorganisms and other biological sources and is widely used in pharmacological, biochemical and drug discovery research.
Natural products remain an important source of bioactive molecules and drug leads. BioCrick provides researchers with high-quality natural product compounds together with catalog numbers, product information and biological activity data.
Hot Products from BioCrick
Showing 361 - 368 of 9359 hot products
| Catalog No. | Product Name |
|---|---|
| BCC2255 | NSC 66811 |
|
Potent MDM2 inhibitor (Ki = 120 nM) which disrupts MDM2-p53 interaction and activates p53 function. Induces p21, p53 and MDM2 accumulation in human colon cancer cells in vitro.
|
|
| BCC2256 | Methylprednisolone |
|
Glucocorticoid receptor (GR) agonist. Displays anti-inflammatory and antioxidant properties. Attenuates apoptosis in oligodendrocytes after injury stimuli. Upregulates expression of Bcl-xL via direct binding of the GR/STAT5 complex. Neuroprotective.
|
|
| BCC2257 | TW-37 |
|
Bcl-2 inhibitor (K<sub>i</sub> values are 0.29 <span class='symbol'>μ</span>M and 1.11 <span class='symbol'>μ</span>M for Bcl-2 and Bcl-XL respectively). Inhibits the angiogenic potential of endothelial cells <em>in vitro</em>. Induces S-phase arrest and apoptosis in pancreatic cancer cell lines; also inhibits the activation of Notch-1 and Jagged-1 <em>in vitro</em> and <em>in vivo</em>.
|
|
| BCC2260 | GW9662 |
|
Selective PPAR<span class='symbol'>γ</span> antagonist (IC<sub>50</sub> values are 3.3, 32 and 2000 nM for PPAR<span class='symbol'>γ</span>, PPAR<span class='symbol'>α</span> and PPAR<span class='symbol'>δ</span> respectively). Blocks the inhibition of osteoclast formation induced by IL-4 in the low micromolar range (1-2 <span class='symbol'>μ</span>M), therefore is more potent than BADGE. Anticancer, inhibits growth of human mammary tumor cell lines.
|
|
| BCC2261 | T0070907 |
|
Potent and selective PPAR<span class='symbol'>γ</span> antagonist (IC<sub>50</sub> = 1 nM). Displays > 800-fold selectivity for PPAR<span class='symbol'>γ</span> over PPAR<span class='symbol'>α</span> and PPAR<span class='symbol'>δ</span>. Blocks transcriptional activity of PPAR<span class='symbol'>γ</span> <em>in vitro</em> and inhibits rosiglitazone-induced adipogenesis.
|
|
| BCC2263 | GSK3787 |
|
Potent and selective peroxisome proliferator-activated receptor <span class='symbol'>δ</span> (PPAR<span class='symbol'>δ</span>) antagonist (pIC<sub>50</sub> = 6.6). Displays no measurable affinity for PPAR<span class='symbol'>α</span> or PPAR<span class='symbol'>γ</span> <em>in vitro</em> (pIC<sub>50</sub>< 5).
|
|
| BCC2264 | Rosiglitazone |
|
Potent and selective PPAR<span class='symbol'>γ</span> agonist (EC<sub>50</sub> = 60 nM); exhibits no activity at PPAR<span class='symbol'>α</span> and PPAR<span class='symbol'>β</span>. Promotes differentiation of pluripotent C3H10T1/2 stem cells into adipocytes. Exhibits antihyperglycemic activity in diabetic <em>ob/ob</em> mouse model. Antidiabetic agent.
|
|
| BCC2265 | WY-14643 (Pirinixic Acid) |
|
Selective PPAR<span class='symbol'>α</span> agonist (EC<sub>50</sub> values are 0.63, 32 and > 100 <span class='symbol'>μ</span>M at PPAR<span class='symbol'>α</span>, PPAR<span class='symbol'>γ</span> and PPAR<span class='symbol'>δ</span> respectively). Negatively inhibits NF-<span class='symbol'>κ</span>B transcriptional activity and decreases the inflammatory response <em>in vitro</em> and <em>in vivo</em>.
|
|